# ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

> **NCT04588311** · PHASE3 · RECRUITING · sponsor: **Australian and New Zealand Intensive Care Research Centre** · enrollment: 2500 (estimated)

## Conditions studied

- Trauma
- Traumatic Injury
- Traumatic Brain Injury
- Wounds and Injuries
- Penetrating Injury
- Blunt Injury
- Major Trauma
- Multiple Trauma

## Interventions

- **DRUG:** Epoetin Alfa 40000 UNT/ML
- **DRUG:** Sodium Chloride 0.9%

## Key facts

- **NCT ID:** NCT04588311
- **Lead sponsor:** Australian and New Zealand Intensive Care Research Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-09
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 2500 (ESTIMATED)
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04588311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04588311, "ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04588311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*